newratings.com  Jun 29  Comment 
FOSTER CITY (dpa-AFX) - An interim analysis of proteinuria data from Anthera Pharmaceuticals Inc.'s (ANTH) phase II proof-of-concept study of Blisibimod in IgA nephropathy, dubbed BRIGHT-SC, has revealed that the trial did not meet...
newratings.com  Jun 29  Comment 
INDIANAPOLIS (dpa-AFX) - A U.S. Food and Drug Administration Advisory Committee voted 12-11 that substantial evidence exists to establish that Jardiance (empagliflozin) reduces cardiovascular or CV death in adults with type 2 diabetes (T2D) and...
Motley Fool  Jun 20  Comment 
Based on a trial of Eli Lilly's SGLT-2 inhibitor, Jardiance, the treatment may significantly reduce heart attacks and strokes for diabetes patients. But it's by no means assured that Lilly will be the big beneficiary of the news.
Motley Fool  Jun 15  Comment 
It's a showdown between the healthcare conglomerate and the diabetes pioneer.
newratings.com  Jun 9  Comment 
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) and Incyte Corp. (INCY) announced that data from a pivotal long-term extension study, RA-BEYOND, was presented at the Annual European Congress of Rheumatology in London. The findings demonstrate...
Benzinga  Jun 8  Comment 
Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine has published detailed results from three pivotal Phase 3 studies—UNCOVER-1, UNCOVER-2 and UNCOVER-3—that demonstrated the efficacy and safety of...
Benzinga  Jun 7  Comment 
Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3 global studies will be presented, along with other...
Motley Fool  Jun 5  Comment 
Both big pharmas are returning to top-line growth, but which is the better buy?

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki